Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-06-12 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a white paper about a new oral contrast agent product by Voyageur Pharmaceuticals. It contains no financial data, no regulatory filing references, no meeting or voting information, no management or board changes, no earnings or interim report data, and no audit or legal proceedings details. It is a product and corporate update aimed at investors and the public, but it is not a financial report or regulatory filing. The document length is 7927 characters, which is relatively short and consistent with a press release or announcement rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-06-12 English
Notice of meeting - English.pdf
Regulatory Filings
2023-06-07 English
Material change report - English.pdf
Regulatory Filings
2023-05-31 English
News release - English.pdf
Regulatory Filings
2023-05-31 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new partnership and development agreement between Voyageur Pharmaceuticals and Rain Cage Carbon. It focuses on the strategic collaboration to develop nanocarbon-based contrast drugs and the use of carbon capture technology. There are no financial statements, regulatory filings, voting results, or management changes reported. The content is promotional and informative about a business development and future plans, typical of a Capital/Financing Update or a general corporate announcement. Given the absence of financial data or regulatory form references, and the focus on a strategic partnership and business development, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2023-05-24 English
Notice of the meeting and record date (amended) - English.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a confirmation notice from TSX Trust Company regarding the record and meeting dates for the upcoming Annual General Meeting (AGM) of Voyageur Pharmaceuticals Ltd. It specifies the meeting date, record dates for notice and voting, and other procedural details related to the AGM. The document does not contain the AGM materials or presentations themselves, nor does it include financial data or voting results. It is a formal announcement about the scheduling and logistics of the AGM, which fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it specifically confirms notice and meeting dates related to the AGM, it aligns best with the Declaration of Voting Results & Voting Rights Announcements (DVA) category, which covers official notices related to shareholder meetings and voting rights. The document length is short (1883 characters), and it is not a report publication announcement or a full report. Therefore, the most appropriate classification is DVA with high confidence.
2023-05-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.